AS IRON SHARPENS IRON

[PINKribbon]

Randy,

Hope you've been enjoying the holiday weekend.

Well, wow, where to start? ...I've only been investing for about two years.

I'm only invested in two companies. Two small companies.

In short, at the beginning of my investment venture, I quickly learned to be cautious of certain ways CEO's do business, toxic financing, diluting, insider buying/selling, and unusually high outstanding share counts.

One of the companies I'm in, PharmaCyte Biotech, has me very excited of it's potential, but I remain "cautiously optimistic".

This particular company has a CEO (Kenneth Waggoner), that at one time in his career, headed a company that eventually became a flop.

However, in following his performance through investigative information found on the internet, from his past to present, I seem to be comfortable with him.

With that said, this company has an incredibly interesting drug/device technology (Cell-in-a-Box®) for helping patients with pancreatic cancer and diabetes.

To be successful with this drug/device and bring it to market, the CEO has put together an amazing international consortium of world renowned scientist and physicians, some who have helped in the development of big pharma(s) existing billion dollar drugs.

Over time, having been successful with studies and trials, and recently having a successful pre-IND meeting with the FDA, the company is about to submit an IND to the FDA for a "pivotal" trial.

Some low points:

Nearly 1 billion OS count
No insider buying
PPS remains low (manipulation???)
Dilution (caused by compensation, compensating company execs, staff, and consortium)

Some high points:

No toxic financing, ever
Amazing progress with drug/device delivery platform
IND filing: http://ir.pharmacytebiotech.com/press-releases/detail/133/pharmacyte-biotech-moves-closer-to-filing-ind-with-naming
Pre-IND meeting with the FDA included: https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html
Possible partnership in place (contingency???)
Janssen (Johnson&Johnson owned) attends multiple presentations (btw, Janssen recently dropped Capricor, and Janssen's Aduro fails trial)
Janssen's growing interest in drug/device delivery platform (Janssen has over 30 chemotherapy drugs and NEEDS a successful delivery platform)
NDA's were signed with big pharma: http://pharmacyte.com/pharmacyte-seeks-to-solve-pancreas-puzzle-with-cell-in-a-box/
PR regarding Johnson & Johnson: http://ir.pharmacytebiotech.com/press-releases/detail/82/johnson-johnson-and-big-pharma-could-find-a-diabetes
PharmaCyte then hired a former J & J exec: http://ir.pharmacytebiotech.com/press-releases/detail/94/pharmacyte-biotech-appoints-former-johnson-johnson
PharmaCyte CEO's recent meetings in Canada (Janssen presence/location).
Bavarian Nordic's recent expansion deal with Janssen: https://finance.yahoo.com/news/bavarian-expands-j-j-deal-084519162.html
Bavarian Nordic is the forerunner to Austrianova (PharmaCyte's owns 14.5% equity interest): http://ir.pharmacytebiotech.com/press-releases/detail/29/pharmacyte-biotechs-cancer-treatment-tumor
J & J has the largest presence in Canada of all pharmaceutical companies: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html
Recently, PharmaCyte appointed Dr. Abecassis to their Board of Directors and Dr. Sher as their Chief Medical Officer:
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-michael-m-abecassis-to-board-of-directors/
http://pharmacyte.com/pharmacyte-biotech-appoints-dr-linda-s-sher-as-chief-medical-officer/

My questions are:
With the possibility of having a partner who obviously has the resources needed for trials, should I be worried about a R/S with the OS shares being at 1billion?
PharmaCyte's executives have been compensated with MILLIONS of shares, so should I be worried that there hasn't been any "insider buying"? (personal cash purchases)

Thank you in advance